Abstract
Abstract Increasing evidence suggests that leptin is involved in regulating immune response by acting as a growth factor on lymphocytes. Previous studies showed reduced number of NK cells in various peripheral organs of leptin-receptor-deficient db/db mice. However, it remains unknown whether leptin-receptor signaling is involved in regulating NK cell development in the bone marrow (BM). In this study, we characterized NK cell development in the BM of db/db mice at a prediabetic stage. Total number of NK cells was moderately reduced in the BM of mutant mice whereas both frequencies and total numbers of NK cell subpopulations were significantly reduced at various differentiation stages. Moreover, BM NK cells from db/db mice displayed markedly increased apoptosis but did not show any defects in cell cycling status and proliferative capacity. Consistently, recombinant leptin could significantly enhance the survival of NK cells of wild-type mice. To verify if NK cell functional activity was impaired in db/db mice, sorting-purified splenic DX5+CD3− NK cells were evaluated for their cytotoxicity and rmIL-15-induced proliferation capacity. Interestingly, db/db NK cells showed unimpaired capacities in their proliferation and cytotoxic function. In conclusion, our findings demonstrate that leptin-receptor deficiency impairs NK cell development in the db/db mouse BM via affecting NK cell survival. This work was supported by grants from the Research Grants Council of Hong Kong (HKU7423/04M).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.